Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7544 in Sepsis-Induced Hypotension
NCT06608901Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in sepsis comparing REGN7544 with Placebo (PB) (2 arms). Primary endpoint: Cumulative vasopressor dose at 72 hours. Started May 2025; status: completed.
02
Drugs
baloncibart
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06608901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608901.